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Adaphostin is a dihydroquinone derivative that is undergoing
extensive preclinical testing as a potential anticancer drug. Pre-
vious studies have suggested that the generation of reactive oxy-
gen species (ROS) plays a critical role in the cytotoxicity of this
agent. In this study, we investigated the source of these ROS.
Consistent with the known chemical properties of dihydroqui-
nones, adaphostin simultaneously underwent oxidation to the
corresponding quinone and generated ROS under aqueous con-
ditions. Interestingly, however, this quinonewas not detected in
intact cells. Instead, high performance liquid chromatography
demonstrated that adaphostin was concentrated by up to 300-
fold in cells relative to the extracellular medium and that the
highest concentration of adaphostin (3000-fold over extracellu-
lar concentrations) was detected in mitochondria. Consistent
with a mitochondrial site for adaphostin action, adaphostin-in-
duced ROS production was diminished by >75% in MOLT-4
rho0 cells, which lackmitochondrial electron transport, relative
to parentalMOLT-4 cells. In addition, inhibition of oxygen con-
sumption was observed when intact cells were treated with ada-
phostin. Loading of isolated mitochondria to equivalent ada-
phostin concentrations caused inhibition of uncoupled oxygen
consumption in mitochondria incubated with the complex I
substrates pyruvate and malate or the complex II substrate suc-
cinate. Further analysis demonstrated that adaphostin had no
effect on pyruvate or succinate dehydrogenase activity. Instead,
adaphostin inhibited reduced decylubiquinone-induced
cytochrome c reduction, identifying complex III as the site of
inhibition by this agent. Moreover, adaphostin enhanced the
production of ROS by succinate-charged mitochondria. Col-
lectively, these observations demonstrate that mitochondrial
respiration rather than direct redox cycling of the hydroqui-
nonemoiety is a source of adaphostin-induced ROS and iden-
tify complex III as a potential target for antineoplastic agents.
Adaphostin (NSC680410) is a dihydroquinone derivative
that is undergoing preclinical testing as a potential anti-leuke-
mic drug. Previous studies have demonstrated that this agent is
toxic to clinical isolates of chronic myelogenous leukemia but
not normal bonemarrow progenitors (1, 2). More recently, this
agent has been reported to retain activity against imatinib-re-
sistant chronic myelogenous leukemia, including cells express-
ing Bcr/Abl mutants that are resistant to currently available
kinase inhibitors (3). Nonetheless, the anti-leukemic activity of
this agent does not depend on the presence of the Bcr/Abl
kinase, as selectivity in killing acute myelogenous leukemia (4)
and chronic lymphocytic leukemia (5) cells is also observed in
vitro. Based on these results, there is considerable interest in
identifying the mechanism by which adaphostin kills cells.
Previous studies (3–6) have suggested that adaphostin kills
target cells through amechanism that involves up-regulation of
reactive oxygen species (ROS).5 Evidence in support of this view
includes increased oxidation of the dyes 5(6)-chloromethyl-
dihydro-2,7-dichlorofluorescein (CM-H2DCF) and dihydro-
ethidium in adaphostin-treated cells, including Bcr/Abl-nega-
tive ML-1 and Jurkat cells, as well as the ability of the
antioxidants N-acetylcysteine (CysNAc), tiron, and Trolox to
inhibit the cytotoxicity of adaphostin (4, 6). On the other hand,
it has also been recognized that dyes such as 5(6)-chloromethyl-
2,7-dichlorofluorescein (CM-DCF) are subject to efflux by
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drug-sensitive transporters (7, 8), raising some doubt regarding
the role of ROS in adaphostin cytotoxicity.
In biological systems, quinones are known to undergo enzy-
matic reduction to semiquinone radicals, which then spontane-
ously oxidize back to quinones, generating superoxide anion in
the process (9–12). These prior observations have led to a gen-
eral assumption that adaphostin might be rapidly oxidized
either extracellularly or intracellularly to a quinone derivative,
which could then generate ROS through redox cycling. Direct
observations testing this hypothesis have not been reported,
however. Moreover, the possibility that leakage of electrons
from themitochondrial electron transport chain, another com-
mon source of ROS (13–15), might contribute to the efficacy of
adaphostin has not been examined previously.
In this study, we confirmed that adaphostin induces oxida-
tive damage of DNA in intact cells and then followed the fate of
adaphostin in solution and in intact cells. The results of this
analysis demonstrate that adaphostin is concentrated several
thousandfold in mitochondria, where it inhibits complex III of
the respiratory chain and leads to mitochondrial ROS genera-
tion. These observations not only provide new insight into the
mechanism of action of a promising anti-leukemic agent, but
also provide additional support for the view that certain inhib-
itors ofmitochondrial respirationmight be potential anticancer
agents.
MATERIALS AND METHODS
Reagents—Adaphostin (NSC680410) and its quinone deriva-
tive were synthesized by the Drug Synthesis and Chemistry
Branch, Division of Cancer Treatment and Diagnosis, NCI,
National Institutes of Health (Bethesda, MD). Reagents were
purchased from the following suppliers: H2O2, tetrapropylam-
monium hydroxide, rotenone, carbonyl cyanide 3-chlorophe-
nylhydrazone (CCCP), pyruvate, sodium succinate, CysNAc,
ascorbic acid, butylated hydroxyanisole, p-iodonitrotetrazo-
lium violet, phenazine methosulfate, decylubiquinone, bovine
heart cytochrome c, carnitine, NAD, thiamine pyrophos-
phate, CoA, bongkrekic acid, N,N,N,N-tetramethyl-p-phe-
nylenediamine, bovine erythrocyte superoxide dismutase, uri-
dine, and catalase from Sigma; buthionine sulfoximine (BSO)
from Chemical Dynamics, Inc. (South Plainfield, NJ);
CM-H2DCF diacetate, dihydroethidium, and the Amplex Red
H2O2 kit (catalog no. A-22188) from Molecular Probes
(Eugene, OR); N-(N-benzyloxycarbonyl-Val-Ala)-Asp(O-
methyl ester)-fluoromethyl ketone from BIOMOL (Plymouth
Meeting, PA); and formamidopyrimidine-DNA glycosylase
from New England Biolabs (Ipswich, MA). All components for
manufacturing a tetraphenylphosphonium cation (TPP)-
selective membrane, including polyvinyl chloride, TPP
sodium salt, and tetrahydrofuran, were from Fluka (Buchs,
Switzerland). 2-[14C]Thymidine (59 mCi/mmol) was from
ICN (Irvine, CA).
Tissue Culture—K562 human leukemia cells and A549 non-
small cell lung cancer cells (American Type Culture Collection,
Manassas, VA) were grown in RPMI 1640 medium containing
5% (v/v) heat-inactivated fetal bovine serum, 100 units/ml pen-
icillin G, 100 g/ml streptomycin, and 2 mM glutamine.
HCT116 human colon cancer cells and OVCAR5 human ovar-
ian cancer cells were propagated in RPMI 1640 medium con-
taining 10% (v/v) heat-inactivated fetal bovine serum, 100
units/ml penicillin G, 100 g/ml streptomycin, and 2 mM glu-
tamine. The MOLT-4 human acute lymphocytic leukemia cell
line and its rho0 derivative, which was generated as described
previously (16), were grown in the samemedium supplemented
with 50 g/ml uridine and 100 g/ml sodium pyruvate.
To assess cell volume, photos of cells were taken using a Zeiss
Axiovert 200M optical morphology microscope. The images
were captured with a Zeiss Axiocam high resolution digital
camera controlled with Zeiss KS400 software, which was used
to measure the diameters of at least 80–100 individual cells
from each line. The volumes of the cells were derived from the
mean diameters and used in calculations to determine ada-
phostin whole cell uptake.
Colony-forming assays, which were performed as described
previously (17, 18), were utilized to determine the effects of
adaphostin on long-term viability of adherent cell lines. In brief,
aliquots containing 350–500 cells were plated in replicate 35-
or 60-mmtissue culture plates and allowed to adhere overnight.
Cells were then treated with the indicated concentrations of
BSO or CysNAc for 4 h, at which time adaphostin was added
(without removal of BSOorCysNAc) for 24 h. At completion of
the incubation, cells were washed, incubated for 7–8 days,
stained with Coomassie Blue, and manually examined for col-
ony formation. Diluent-treated plates typically contained 150–
250 colonies.
Assessment of Intracellular ROS—CM-H2DCF diacetate
(a cell-permeant non-fluorescent compound that diffuses
into cells, undergoes de-esterification, and is oxidized to the
fluorescent dye CM-DCF) was used to assess changes in rela-
tive intracellular ROS levels. After exposure to drugs for the
indicated times, cells were collected by centrifugation, incu-
bated with 10 M CM-H2DCF diacetate in calcium- and mag-
nesium-free Dulbecco’s phosphate-buffered saline (DPBS) for
30min in the dark at 37 °C, washed with DPBS, read on the FL1
channel of a BD Biosciences FACSCalibur, and analyzed using
BD Biosciences CellQuest software.
Measurement of Adaphostin-mediated Superoxide and Per-
oxide Generation in Vitro—Superoxide radical generation was
assessed using a cytochrome c reduction assay (19). Briefly, the
reaction was initiated by the addition of adaphostin or diluent
to a 1-ml mixture containing 50 M oxidized cytochrome c and
50mMTris-HCl (pH8.0) in the absence or presence of 30g/ml
bovine erythrocyte superoxide dismutase. The level of superox-
ide generationwas estimated from the difference in absorbance
at 550 and 418 nm, which was measured after 1 h of incubation
at 21 °C. Generation of H2O2 in solution was assessed using an
Amplex Red assay, which monitors peroxidase-catalyzed oxi-
dation of Amplex Red to resorufin (20), as described by the
supplier. Known concentrations of H2O2 provided a standard
curve.
Alkaline Elution with Formamidopyrimidine-DNA Glycosy-
lase (Adapted from Refs. 21 and 22)—Logarithmically growing
cells were labeled for 24 h with 1 M [14C]thymidine, sedi-
mented, and incubated for 1–2h at 37 °C in fresh culturemedium.
After incubation for 30min at 37 °Cwith the indicated concentra-
tions of adaphostin, H2O2, or vehicle, cells (200,000/aliquot)
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were deposited on Nucleopore phosphocellulose filters
(1-m pore size; VWR Scientific Products, Minneapolis,
MN) by gentle suction. Cells were washed with 20 ml of ice-
cold pre-lysis buffer (0.075 M NaCl and 0.024 M Na4EDTA (pH
7.4)) and lysed by allowing 5 ml of buffer A (2% (w/v) SDS, 100
mM glycine, and 25 mM EDTA (pH 10)) to drip through the
filters over 30 min. After the filters were washed with 25 ml of
buffer B (40 mM HEPES-KOH (pH 8.0), 0.1 M KCl, 0.5 mM
EDTA, and 0.2 mg/ml bovine serum albumin), 2 ml of buffer B
containing 8 units/ml formamidopyrimidine-DNA glycosylase
was added to each filter, which was then incubated at 37 °C for
30min andwashedwith an additional 25ml of buffer B. Prior to
elution, 5 ml of buffer A with 0.5 mg/ml proteinase K was
allowed to drip through the filter over 30min. Filters were then
washed with 20 mM EDTA (pH 10), and DNA was eluted with
20mM EDTA (adjusted to pH 12.1 with tetrapropylammonium
hydroxide). The distribution of radiolabel in the eluate, the tub-
ing of the elution apparatus, and the filter was analyzed as
described by Covey et al. (23). Cells that received 150–900 cen-
tigrays of -irradiation from a 137Cs source were included in
each experiment to provide a standard curve.
Analysis of Adaphostin Degradation in DPBS—Adaphostin
was added to DPBS and incubated as indicated below. Aliquots
were injected onto a Beckman System Gold HPLC system and
separated on a Beckman Ultrasphere ODS 5-m column (4
mm  25 cm) by isocratic elution with a mobile phase consist-
ing of 1:1 acetonitrile and 2.5 mM ammonium formate (pH 4).
Elution was monitored by absorbance at 305 nm.
Liquid Chromatography-Tandem Mass Spectrometry (LC-
MS/MS) Analysis—The LC/MS system consisted of a Shi-
madzu HPLC system containing two LC-10ADvp pumps and
an SIL-10ADvp autoinjector (injection volume of 60 l) cou-
pled to a Quattro micro triple quadrupole mass spectrometer
(Waters Corp., Milford, MA). Separation was performed using
a Brownlee NewGuard RP-18 7-mpre-column (15 3.2mm;
Chrom Tech, Apple Valley, MN) and a Genesis Lightning C18
120A 4-m analytical column (10 cm  2.1 mm; Jones Chro-
matography, Lakewood, CO). The mobile phase (flow rate of
0.20 ml/min) consisted of acetonitrile and 0.625 mM formate
buffer (pH 4), initially at a 40:60 (v/v) ratio for 40 min and then
ramped to 60% acetonitrile and held for 10 min.
Ionizations of adaphostin and the quinone of adaphostin
were accomplished using an electrospray ionization probe
operating in positive mode. Detection was accomplished by
MS/MS using a daughter ion spectrum scan (m/z 45–450),
looking for daughters of the specific parent ions atm/z 394 and
392 for adaphostin and the quinone, respectively. The scan
time, cone voltage, and collision energy values were, 1.0 s, 30 V,
and 15 eV, respectively. The source temperature, desolvation
temperature, cone gas flow, and desolvation gas flow were
100 °C, 120 °C, 100 liters/h, and 250 liters/h, respectively. LC-
MS/MSdatawere collected from5 to 55min after sample injec-
tion. Spectra and chromatograms were processed usingMicro-
mass MassLynx Version 3.5 software.
Cell Fractionation and Isolation of Mitochondria from K562
Cells (Adapted from Ref. 24)—All steps were performed at 4 °C.
K562 cells (108) were harvested by centrifugation at 100  g
for 5 min, washed twice with ice-cold DPBS, and resuspended
in 5ml of buffer C (20mMHEPES-KOH (pH 7.5), 10mMKCl, 3
mMMgSO4, 1mM EDTA, 1mM EGTA, 1mM dithiothreitol, 0.1
mM -phenylmethylsulfonyl fluoride, and 250 mM sucrose).
After 20 min on ice, cells were homogenized in a tight-fitting
Dounce homogenizer until lysed (50 strokes). After the homo-
genate was sedimented at 800  g, the pellet containing unbro-
ken cells and nuclei was discarded, and the supernatant was
sedimented at 10,000  g for 15 min at 4 °C to obtain the mito-
chondrial fraction, which was resuspended in 5 ml of ice-cold
buffer C and placed on ice for 15–30 min until used. The post-
mitochondrial supernatant was sedimented at 100,000  g for
1 h to separate themicrosomal fraction (pellet) from the cytosol
(supernatant). Alternatively, rat liver mitochondria were iso-
lated by differential centrifugation as described (25, 26).
Measurement of Adaphostin Content in Cellular Fractions—
After 6 volumes of acetonitrile was added to 1 volume of each
subcellular fraction, samples were mixed thoroughly and cen-
trifuged at 14,000 g for 5min. The supernatant was subjected
toHPLC as described abovewith known concentrations of ada-
phostin as a standard. The pellet was hydrolyzed in 0.5 MNaOH
and assayed for protein.
Measurement of m of Isolated Mitochondria Using a
TPP-selective Electrode—The membrane potential and respi-
ration of isolated mitochondria were recorded using a proto-
type multichannel recorder (ABMT-USA, Inc., Durham, NC).
m was measured in incubation medium containing 200 mM
mannitol, 75 mM sucrose, 5 mM KH2PO4, 5 mM pyruvate, 5 mM
malate, 2 mMMgCl2, 1 mM EGTA, and 10mMMOPS (pH 7.35)
using a home-made TPP-sensitive mini-electrode as de-
scribed (27). Briefly, mitochondria (1 mg/ml protein) were
added to the incubation medium containing 500 M TPP chlo-
ride.  was calculated from the TPP electrode reading
according to the following equation:   59 log(/V)  59
log(10(EE0)/59  1), where is themitochondrial membrane
potential (in millivolts);  is the mitochondrial matrix volume
(1.6l/mgofmitochondrial protein) (28);V is the volumeof the
incubation medium (1 ml); and E0 and E are electrode poten-
tials (in millivolts) before and after the addition of mitochon-
dria, respectively (29). Adaphostin up to 25 M and vehicle
(Me2SO) up to 0.5% (v/v) did not interfere with the readings of
the TPP-sensitive electrode. Only electrodes that exhibited a
Nernstian response were used.
Oxygen Consumption—Mitochondria were suspended at a
concentration of 1 mg/ml protein in mitochondrial incubation
buffer (MIB) consisting of 200 mM mannitol, 75 mM sucrose, 5
mM KH2PO4, 2 mM MgCl2, 1 mM EGTA, and 10 mM MOPS-
KOH (pH 7.35). K562 cells were suspended in cell culture
medium at a concentration of 107 cells/ml. Oxygen con-
sumption was measured using a Clark-type electrode (Model
5300, YSI Inc.). All measurements were performed at room
temperature.
Dehydrogenase Assays—Succinate dehydrogenase activity
was assayed as described (30). Briefly, mitochondria (1 mg of
protein) were suspended in 1 ml of reaction buffer containing
50mMpotassiumphosphate (pH 7.4), 50mM sodium succinate,
25 mM sucrose, 2 mM EDTA, and 0.1% (w/v) p-iodonitrotetra-
zolium violet and incubated on ice for 30 min. Following the
addition of adaphostin, the suspension was incubated at 37 °C
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for 15 min. After the reaction was terminated with 1 ml of 10%
(w/v) trichloroacetic acid, the product was extracted into 4 ml
of ethyl acetate and assayed at 490 nm.
Pyruvate dehydrogenase activity was measured as described
by Schwab et al. (31). Briefly, mitochondria (4 mg/ml protein)
were suspended in buffer consisting of 0.1% (v/v) Triton X-100,
1 mM CaCl2, 5 mM MgCl2, 50 mM KCl, 250 mM sucrose, and 20
mM Tris-HCl (pH 7.5). After three freeze-thaw cycles, mito-
chondria were incubated at 37 °C for 10 min to activate pyru-
vate dehydrogenase. Aliquots of the mitochondrial suspension
(50 l) were added to the wells of a microtiter plate, and the
reaction was started by the addition of 250 l of reaction buffer
containing 5 mM L-carnitine, 2.5 mM NAD, 0.2 mM thiamine
pyrophosphate, 0.1 mM CoA, 5 mM pyruvate, 0.1% (v/v) Triton
X-100, 1 mM MgCl2, 0.1% bovine serum albumin, 0.6 mM p-io-
donitrotetrazolium violet, and 6.5 M phenazine methosulfate
in 0.05 M potassium phosphate (pH 7.5). Activity was estimated
from the changes in absorbance (A500  A700).
Complex III ActivityMeasurement—Complex III activity was
assessed by monitoring the reduction in cytochrome c meas-
ured as changes in absorbance (A550  A540) in the presence of
reduced decylubiquinone (32). To synthesize reduced decylu-
biquinone, a small crystal of sodium borohydride was added to
200 l of 10 mM decylubiquinone (oxidized form). 5 l of 0.1 M
HCl was added, and the reaction was mixed until the yellow
solution became colorless. The reduced decylubiquinone
(supernatant) was transferred to a fresh tube, diluted with 5 ml
of 1 M HCl, and stored in the dark until used. To assay complex
III activity, mitochondria (30 g/ml protein) were resuspended
in reaction buffer containing 250 mM sucrose, 1 mM EDTA, 50
mM Tris-HCl (pH 7.4), 50 M cytochrome c, and 2 mM KCN at
21 °C. The reaction was initiated by the addition of 50 M
reduced decylubiquinone, and complex III activity was meas-
ured by monitoring changes in absorbance (A550  A540) over
3 min.
ROS Generation by Isolated Mitochondria—Rat liver mito-
chondria (1 mg/ml protein) in MIB supplemented with 5 mM
succinate were snap-frozen in liquid nitrogen and thawed three
times at 30 °C. After he addition of adaphostin and/or catalase,
samples were incubated for 1 h at 30 °C. The concentration of
H2O2 generated was assayed using Amplex Red (20) as
described above.
Docking of Adaphostin into the Drug-binding Sites of the
Cytochrome bc1 Complex in Silico—Four different conforma-
tions of adaphostin were docked into two binding sites of the
heme bH-containing cytochrome b subunit of the cytochrome
bc1 complex using the EUDOC program with rotational and
translational increments of 10° of arc and 0.5 Å, respectively
(33). The atomic charges of adaphostin were generated accord-
ing to the RESP procedure (34) with ab initio calculations at the
HF/6-31G* level using the Gaussian 03 program (35). The ada-
phostin conformations were generated by systematically alter-
ing the conformation-governing torsions and subsequently
optimized by energy minimizations using the force field
(parm99.dat) of Cornell et al. (36) and the SANDER module of
AMBER5 (37). The energy minimizations were monitored for
reaching local minimum conformations with a normal mode
analysis using the NMODE module of AMBER8 (37) and then
terminated when the analysis showed that adaphostin reached
a local minimum potential energy conformation. The first
binding site of the holocytochrome b subunit, reported as the
quinone reduction (Qi) site (38), was taken from a crystal struc-
ture of the subunit containing antimycin A in the Qi site (Pro-
tein Data Bank code 1NTK). The docking box (6.0  6.0  6.0
Å3) at the Qi site was defined to be surrounded by Phe18, Ser35,
Leu197, and heme bH. The second binding site of the holosub-
unit, reported as the quinol oxidation (Qo) site (39), was
obtained from a crystal structure of the subunit containing
azoxystrobin in theQo site (ProteinData Bank code 1SQB). The
docking box (6.0 6.0 6.0 Å3) at theQo site was defined to be
surrounded by Phe128, Tyr131, Ile146, Pro270, and Phe274. The
EUDOC-generated adaphostin complex with the lowest inter-
action energy was then refined with 20 different molecular
dynamics simulations (1.0 ns for each simulation with a 1.0-fs
time step and different initial velocities) according to a pub-
lished procedure (40) using the PMEMD module of AMBER8.
FIGURE 1. Adaphostin induces ROS production and oxidative DNA damage. A, K562 cells treated with adaphostin or diluent for 30 min were stained with
CM-H2DCF diacetate and subjected to flow cytometry. B, K562 cells were treated with diluent or 10 M adaphostin in the absence or presence of 50 M
N-(N-benzyloxycarbonyl-Val-Ala)-Asp(O-methyl ester)-fluoromethyl ketone (zVAD(OMe)fmk) or 50 M bongkrekic acid for 30 min. Relative intracellular ROS
levels were assessed using CM-H2DCF diacetate. C, after K562 cells were treated with diluent, 10 M adaphostin, or 10 M H2O2 for 30 min, the presence of
8-oxoguanine was assessed by alkaline elution with or without formamidopyrimidine-DNA glycosylase (Fpg). Elution of DNA through the filters was compared
with elution after irradiation of K562 cells with 400 – 800 centigrays of ionizing radiation. Error bars represent the means 	 S.D. of three to five independent
determinations.
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An average of 10,000 trajectories
obtained at 1.0-ps intervals during
the last 0.5-ns period of the 20 sim-
ulations was used as the refined
three-dimensional model of the
adaphostin complex.
Statistical Analysis—Values pro-
vided below represent the means 	
S.D. of at least three independent
experiments. Error bars in individ-
ual figures represent the means 	
S.D. of the number of independent
experiments indicated in the corre-
sponding figure legends.
RESULTS
Adaphostin Increases the Levels of
ROS within Cells—Previous studies
suggested that adaphostin causes an
increase in intracellular ROS levels (4,
6). Consistent with these results,
treatment of K562 human leukemia
cells with 10 M adaphostin for 30
min caused an increase in CM-DCF
fluorescence to 230 	 40% of control
values (mean	 S.D., n 5) (Fig. 1,A
and B). This increase in ROS was not
significantly altered when cells were
treated with adaphostin in the pres-
ence of themitochondrial permeabil-
ity transition inhibitor bongkrekic
acid or the broad-spectrum caspase
inhibitor N-(N -benzyloxycarbonyl-
Val-Ala)-Asp(O-methyl ester)-flu-
oromethyl ketone (Fig. 1B), placing
the ROS generation upstream of
mitochondrial permeability transi-
tion and caspase activation.
Because alternative explanations,
including adaphostin-induced inhi-
bition of CM-DCF transporters (7,
8), might account for the increased
CM-DCF fluorescence, additional
experiments using alternative
methods were performed to verify
that adaphostin induced an increase
in intracellular ROS levels. In par-
ticular, after cells were treated with
vehicle or adaphostin, DNA was
subjected to filter elution in the
absence or presence of formami-
dopyrimidine-DNA glycosylase, an
enzyme that recognizes and cleaves
at 8-oxoguanine residues (41). As
indicated in Fig. 1C, the increase in
strand breaks detected in DNA
from adaphostin-treated cells after
formamidopyrimidine-DNA glyco-
FIGURE 2. Adaphostin generates ROS in DPBS and undergoes chemical transformation. A, adaphostin (Ada;
100 M) was added to buffer consisting of 50 M cytochrome c in 50 mM Tris-HCl (pH 8) in the absence or presence
of 30 g/ml superoxide dismutase (SOD). After incubation for 1 h, the level of reduced cytochrome c was measured
as the absorbance difference at 550 and 418 nm. B, shown is the H2O2 generation by 100 M adaphostin during a 1-h
incubation in DPBS. Amplex Red oxidation was assessed spectrophotometrically and compared with results
obtained with known amounts of H2O2. C, adaphostin was added to DPBS and incubated for 7 h at room tempera-
ture. Aliquots were removed and subjected to HPLC. D, shown are the results from LC-MS/MS analysis of adaphostin
(upper panel) and the product shown in C (lower panel). Positive electrospray ionization was used to generate the
precursor ions MH  394 (upper panel) and MH  392 (lower panel), which were then subjected to collision-
induced dissociation to produce the daughter ions shown in these product spectra. The adaphostin structure (upper
panel), the deduced structure of the product (lower panel), and the collision-induced dissociation fragmentation
resulting in the observed product ions are shown in the insets. The retention time and daughter ion spectrum of the
product were identical to those of the bona fide quinone of adaphostin. E, adaphostin was added to DPBS and
incubated at room temperature. Aliquots removed at the indicated time points were subjected to HPLC to assess
adaphostin and quinone concentrations. Left panel, results showing the parent adaphostin and quinone measured
simultaneously; right panel, pooled results of four experiments. Error bars represent the means 	 S.D. of three (A and
B) and four (E) independent determinations.
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sylase incubationwas similar to that detected inDNA fromcells
treated with 10 M H2O2, providing independent evidence of
adaphostin-induced oxidative stress. Collectively, all of the
results in Fig. 1 suggest that cells treated with adaphostin sus-
tain oxidative damage.
Fate of Adaphostin in Aqueous Media—To identify the ROS
causing this damage, we initially examined the fate of adaphos-
tin in aqueous buffer. When adaphostin was incubated in
DPBS, multiple assays indicated the presence of increased ROS
levels. In preliminary experiments, the addition of adaphostin
to DPBS containing 2-methyl-6-(4-methoxyphenyl)-3,7-dihy-
droimidazo[1,2-a]pyrazin-3-one resulted in increased lumi-
nescence indicative of increased ROS levels (data not shown).
Likewise, the oxidation of dihydroethidium to the fluorescent
compound ethidium was increased by adaphostin. Because
these assays do not clearly distinguish between superoxide
anion and peroxides, two ROS that could potentially be gener-
ated during adaphostin oxidation, we employed more selective
assays in additional experiments. As shown in Fig. 2A, adaphos-
tin induced a reduction in cytochrome c. The ability of purified
superoxide dismutase to blunt this reduction suggests that ada-
phostin generates superoxide anion in solution. Likewise, ada-
phostin enhanced the peroxidase-mediated oxidation of
Amplex Red to resorufin (Fig. 2B), suggesting that adaphostin
also induces generation of H2O2.
To determine the basis for the generation of these ROS, the
fate of adaphostin was followed by HPLC. During the course of
incubation inDPBS at ambient oxygen tension, the parent com-
pound disappeared, with a half-life of 8	 2 h (mean	 S.D., n
4), and a new peak appeared (Fig. 2, C and E). Based on a 2-Da
decrease in the size of the parent ion and the fragmentation
observed during LC-MS/MS, the new peakwas identified as the
quinone derivative of adaphostin (Fig. 2D). Additional experi-
ments indicated that chemically synthesized quinone had an
indistinguishable retention time and collision-induced dissoci-
ation spectrum during LC-MS/MS (data not shown). Time
course experiments indicated that the quinone concentration
peaked at 6.2 	 0.4 h (n  3) and subsequently declined as this
compound was oxidized even further (Fig. 2E). Collectively,
these observations indicate that adaphostin in aqueous buffers
is oxidized to the corresponding quinonewith concomitant for-
mation of superoxide and H2O2.
Fate of Adaphostin in Intact Cells—Armedwith the informa-
tion that adaphostin can be converted to the corresponding
quinone,wenext examined the fate of adaphostin in intact cells.
For this analysis, K562 cells (106/ml) were treated with 2.5 M
adaphostin for periods of up to 4 h, extensively washed, and
then extracted for HPLC analysis. In contrast with results
obtained when adaphostin was incubated in DPBS (Fig. 2), the
quinone could not be detected in the reducing environment of
intact cells (Fig. 3A). Instead, only the parent drug was detected
(Fig. 3A). Notably, however, this analysis also indicated that
adaphostin was concentrated by 300	 30-fold (n 3) in intact
K562 cells relative to the extracellular medium (Fig. 3B). As a
consequence, 38 	 8% of the total drug added to the tissue
culture medium was recovered with the cell pellet under the
conditions of this incubation (Fig. 3C).
Using the approach described under “Materials and Meth-
ods,” the subcellular distribution of adaphostin was examined
by cell fractionation. As indicated in Fig. 3D, over half of all
adaphostin taken into cells was recovered in the mitochondrial
fraction. Assuming a mitochondrial volume of 1.6 l/mg of
mitochondrial protein (28), the final concentration of adaphos-
tin in mitochondria was 9.2 	 3.3 mM after treatment of the
cells with 2.5 M extracellular adaphostin, indicating an
3000-fold concentration of drug in mitochondria. Time
course experiments demonstrated that this dramatic uptake of
adaphostin into mitochondria occurred in 
30 min and per-
sisted for at least 2–3 h (Fig. 3E). Further analysis demonstrated
that similarmitochondrial concentrations could be achieved by
incubating isolated mitochondria with 200 M adaphostin
under cell-free conditions, providing a means of reproducing
the effects of adaphostin under cell-free conditions in the
experiments described below.
FIGURE 3. Adaphostin uptake into K562 cells. A, K562 cells were treated
with 2.5 M adaphostin for 30 min. Adaphostin uptake was analyzed by HPLC
as described under “Materials and Methods.” B, based on HPLC analysis, the
concentration of adaphostin in the extracellular medium and cells was calcu-
lated. C, based on the experiment in B, the percentage of total adaphostin in
the extracellular medium and cells is shown. D, after K562 cells were treated
with 2.5 M adaphostin for 30 min, subcellular fractions were isolated. Ada-
phostin content was measured in each fraction by HPLC. E, after K562 cells
were treated with 2.5 M adaphostin for different lengths of time, mitochon-
dria were isolated. The amount of adaphostin in mitochondria was assessed
by HPLC and is expressed in millimolar concentrations based on the assump-
tion of a mitochondrial volume of 1.6 l/mg of mitochondrial protein (28).
Error bars represent the means 	 S.D. of three independent determinations.
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Effect of Adaphostin on Mitochondrial Respiration—To
assess whether adaphostin might alter mitochondrial function,
we initially examined the effect of adaphostin on oxygen con-
sumption in intact cells. In brief, the respiration of K562 cells
was assessed using a closed chamber and a Clark-type oxygen
sensor. The oxygen consumption of diluent- or adaphostin-
treated cells was monitored in the absence and presence of
CCCP, an uncoupler of mitochon-
drial oxidative phosphorylation. As
indicated in Fig. 4A, adaphostin
diminished the CCCP-uncoupled
oxygen consumption rate in intact
cells by 59 	 8% (n  3), raising the
possibility that adaphostin might
affect mitochondrial function.
To further analyze this possibil-
ity, we examined the effect of ada-
phostin on ADP-induced depolar-
ization of isolated mitochondria
using an ion-sensitive electrode (26,
27). These and subsequent experi-
ments utilized mitochondria from
rat liver because of the ability to iso-
late large quantities of highly puri-
fied organelles from this tissue. The
addition of 300 M ADP to these
mitochondria resulted in transient
depolarization during the period
of ATP synthesis, followed by
repolarization to a steady-state
m of 170 mV (Fig. 4B, upper
panel). Treatment with 25 M ada-
phostin caused prolongation of
the ADP-induced mitochondrial
depolarization (Fig. 4B, lower
panel), suggesting that adaphostin
might inhibit some component of
the mitochondrial respiratory
chain, nucleotide exchange, or
mitochondrial F0F1-ATPase.
To examine the action of ada-
phostin on mitochondria in greater
detail, the rate of oxygen consump-
tion by isolated mitochondria was
examined in the presence of various
respiratory substrates. As indicated
in Fig. 4C (inset), when mitochon-
dria were incubated with the com-
plex I substrates pyruvate and
malate, adaphostin diminished
ADP-induced mitochondrial oxy-
gen consumption in a dose-depend-
ent manner. On average, 200 M
adaphostin, which resulted in the
same mitochondrial drug concen-
tration as observed in intact cells
treated with 2.5 M adaphostin,
caused a 48	 2% (n 3) decrease in
ADP-stimulated respiration (Fig. 4C). When the complex II
substrate succinate was substituted for pyruvate and malate,
adaphostin likewise caused a 63.2 	 2.5% (n  3) decrease in
ADP-stimulated respiration (Fig. 4C). Moreover, adaphostin
also inhibited CCCP-stimulated oxygen consumption in the
presence of the same substrates (Fig. 4C). Because CCCP
uncouples electron transport and ATP synthesis, making oxy-
FIGURE 4. Adaphostin inhibits mitochondrial respiration. A, effect of adaphostin on oxygen consumption in
intact K562 cells. K562 cells (107/ml) were added to a closed chamber with an oxygen electrode at room
temperature. After the addition of diluent (dimethyl sulfoxide (DMSO)) or adaphostin (ada) and 1 M CCCP,
oxygen levels were monitored, and the rate of oxygen consumption was calculated. B, isolated rat liver mito-
chondria were added to a TPP-containing solution supplemented with diluent or 25 M adaphostin in a
cuvette with a TPP-sensitive electrode for measurement of mitochondrial transmembrane potential. At the
indicated times, 300 M ADP was added. DNP (2,4-dinitrophenol; 10 M) was subsequently added to dissipate
the transmembrane proton gradient. The time required for mitochondria to recover from depolarization ()
was delayed in the presence of 25 M adaphostin. C, isolated rat liver mitochondria were added to buffer
containing either 5 mM succinate and 1 M rotenone or 5 mM pyruvate (Pyr) and 5 mM malate in the absence or
presence of 100 M adaphostin. The oxygen level was measured using a Clark-type electrode. After 1 min, 300
M ADP or 0.4 M CCCP was added. The rate of oxygen consumption by mitochondria was calculated after the
addition of respiration stimuli (CCCP or ADP) and is expressed as nanomoles/min/mg of mitochondrial protein.
Inset, plot of oxygen level versus time after the addition of CCCP in the presence of diluent or different ada-
phostin concentrations. Note that treatment of mitochondria with 200 M adaphostin under cell-free condi-
tions resulted in mitochondrial levels similar to those obtained by treating whole cells with 2.5 M adaphostin.
D, after isolated rat liver mitochondria were subjected to three cycles of freezing in liquid nitrogen, aliquots
were added to MIB containing 1 mM NADH, and oxygen levels were measured using a Clark-type electrode.
Adaphostin (200 M) or diluent was added after 1 min. The rate of oxygen consumption by mitochondria after
the addition of adaphostin or diluent was calculated. Error bars represent the means 	 S.D. of three to five
independent determinations.
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gen consumption independent of ATP generation, the
observed ability of adaphostin to inhibit respiration of CCCP-
treated mitochondria argued against the possibility that ada-
phostin inhibits the adenine nucleotide transporter or
F0F1-ATPase.
A series of additional experiments were performed to further
delineate the adaphostin-sensitive step in mitochondrial respi-
ration. In these experiments, adaphostin failed to inhibit the
succinate and pyruvate dehydrogenase complexes directly (Fig.
5, A and B), suggesting that the block is downstream of dehy-
drogenase activity. Moreover, when mitochondria were frozen
and thawed repeatedly to disrupt the inner mitochondrial
membrane, rendering it freely permeable to NADH (42, 43),
adaphostin inhibited NADH-stimulated oxygen consumption
(Fig. 4D), confirming that the effect of adaphostin is mediated
by direct inhibition of mitochondrial electron transfer rather
than inhibition of tricarboxylic acid cycle dehydrogenases.
Additional experiments (not shown) failed to demonstrate any
inhibition of oxygen consumption when isolated intact mito-
chondria were incubated with 1 mM ascorbic acid in the pres-
ence of N,N,N,N-tetramethyl-p-phenylenediamine, which
transfers electrons to cytochrome c (44, 45), confirming that
electron transfer from cytochrome c to cytochrome c oxidase to
molecular oxygen was intact.
Collectively, the preceding experiments suggested that ada-
phostin might inhibit complex III. To test this hypothesis more
directly, complex III activity was assessed by monitoring cyto-
chrome c reduction in the presence of reduced decylubiqui-
none. Like the selective complex III inhibitor antimycin A (46),
adaphostin inhibited decylubiquinone-induced cytochrome c
reduction (Fig. 6).
Adaphostin Fits into the Qi Site of Complex III—To gain fur-
ther insight into the potential interaction of adaphostin with
complex III, the docking ofmultiple conformations of adaphos-
tin into two known binding sites of the heme bH-containing
cytochrome b subunit of the cytochrome bc1 complex (38, 39)
was analyzed in silico. This analysis suggested that adaphostin
preferentially binds to the Qi site (28 kcal/mol for the Qi site
versus more than 5 kcal/mol for the Qo site). In the refined
three-dimensional model of the adaphostin complex with an
intermolecular interaction energy of 47.3 kcal/mol (EvdW 
45.6 kcal/mol and Eele  1.7 kcal/mol), the adamantyl
group of adaphostin has van der Waals interactions with the
methyl group of heme bH and with the side chains of Gly38,
Leu41, Ile42, Met190, and Met194; the middle and terminal aro-
matic groups of the drug form - interactions with the side
chains of Phe18 and Phe220, respectively; the meta-hydroxyl
group of the drug has a water-bridged hydrogen bond with
Asn32 and Ser35; and the ortho-hydroxyl group has a water-
bridged hydrogen bond with Ser205 (Fig. 7A). Interestingly, the
binding mode of adaphostin is very similar to that of antimycin
A, as shown in Fig. 7 (B and C), even though the adaphostin
model was computationally developedwithout any assumption
that adaphostin shares the binding mode of antimycin A.
Generation of ROS by Adaphostin-treated Mitochondria—
The preceding analysis suggested that inhibition of complex III
is a primary effect of adaphostin. To rule out the alternative
hypothesis that the effects of adaphostin on mitochondrial res-
piration are due to adaphostin-induced spontaneous genera-
tion of ROS in solution (Fig. 2), followed by ROS-induced inhi-
bition of respiration (47), the effect of adaphostin on
mitochondrial oxygen consumption was examined in the
absence and presence of butylated hydroxyanisole or CysNAc,
two antioxidants with different chemical structures. As indi-
cated in Fig. 8A, neither of the antioxidants reversed the inhib-
itory effect of adaphostin on mitochondrial respiration. These
results provide further evidence that inhibition of mitochon-
drial respiration is a primary effect of adaphostin rather than a
consequence of ROS generation.
An additional series of experiments assessed whether the
effects of adaphostin on mitochondrial function (Figs. 4–6)
could contribute to the increased ROS levels observed in intact
cells (Fig. 1). For these experiments, H2O2 production (13, 47)
was assessed aftermitochondria were incubatedwith diluent or
adaphostin in the absence or presence of catalase. Consistent
with our previous results (Fig. 2B), adaphostin by itself gener-
ated H2O2 in solution (Fig. 8B). In the presence of mitochon-
dria, however, the amount of ROS generated increased at least
7-fold, suggesting that the effects of adaphostin on mitochon-
FIGURE 5. Adaphostin fails to inhibit succinate or pyruvate dehydroge-
nase. A, after 100 M adaphostin or diluent was added to isolated rat liver
mitochondria, succinate dehydrogenase (A) or pyruvate dehydrogenase (B)
activity was measured as described under “Methods and Materials.” Error bars
represent the means 	 S.D. of three independent determinations.
FIGURE 6. Adaphostin inhibits complex III in the mitochondrial respira-
tory chain. Rat liver mitochondria were assayed for site III activity as meas-
ured by reduced decylubiquinone-induced cytochrome c reduction in the
presence or absence of 100 M adaphostin. Antimycin (a known inhibitor of
complex III activity) was used at 5 g/ml as a positive control. Error bars rep-
resent the means 	 S.D. of three independent determinations.
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drial respiration contribute substantially to ROS generation by
this agent.
To further examine the role of mitochondrial electron trans-
port in adaphostin-induced ROS, the MOLT-4 human leuke-
mia cell line and a rho0 derivative that lacksmitochondrial elec-
tron transport as a consequence of loss of mitochondrial DNA
(16) were compared. Consistent with results in other cell lines
(Fig. 1) (4, 6), treatment of MOLT-4 cells with 10 M adaphos-
tin for 30 min caused an increase in CM-DCF fluorescence to
200 	 11% of control values (mean 	 S.D., n  4) (Fig. 8,C and
D). In contrast, treatment of MOLT-4 rho0 cells with adaphos-
tin resulted inmore uptake into cells (Fig. 8D, inset), but caused
only a 24	 14% increase inCM-DCF fluorescence (Fig. 8,C and
D), suggesting that 75% of the adaphostin-induced increase in
ROS levels in parentalMOLT-4 cells depends on ongoingmito-
chondrial electron transport.
ROS-dependent Cytotoxicity in Solid Tumor Cell Lines—Be-
cause the ability to inhibit complex III and to increase ROS
levels should not be limited to leukemia cell lines, we examined
the effect of adaphostin in widely studied solid tumor cell lines.
As indicated in Fig. 9A, treatment of HCT116 human colon
adenocarcinoma cells with 10M adaphostin for 30min caused
an increase in CM-DCF fluorescence to 195 	 7% of control
values (mean 	 S.D., n  4). Additional experiments (not
shown) indicated that adaphostin was concentrated 80-fold in
these cells relative to the extracellular medium. To assess the
impact of the increased ROS levels, cells were exposed for 24 h
to adaphostin, washed, and assayed for the ability to subse-
quently proliferate into colonies. Treatment with adaphostin
inhibitedHCT116 colony formation in a dose-dependentman-
ner (Fig. 9C), with IC90  17 	 3 M (mean 	 S.D., n  4).
CysNAc at 6 mM, one-fourth of the concentration used previ-
ously (4), diminished the anti-proliferative effects at the highest
adaphostin concentration tested (Fig. 9C).6 Conversely, gluta-
thione depletion with BSO diminished the IC90 by 4.5 	 1.9-
fold (mean 	 S.D., n  4). In A549 non-small cell lung cancer
cells, which took up 8-fold less adaphostin than HCT116 cells,
the increase in ROS levels after exposure to 10 M adaphostin
was much lower (Fig. 9B), and the anti-proliferative effects of
adaphostin were less potent (Fig. 9D), with IC90  33 	 3 M
(n  3). Nonetheless, treatment with CysNAc at 24 mM pro-
tected the cells atmultiple adaphostin concentrations, andBSO
treatment again diminished the IC90 by a factor of 7.65 	 1.2
(n  3) (Fig. 9D). Similar results were observed in OVCAR5
ovarian cancer cells (data not shown). Collectively, these results
indicate that adaphostin is concentrated in solid tumor cell
lines, that it generates ROS, and that the ability of solid tumor
cells to detoxify these ROS plays an important role in resistance
to this agent.
DISCUSSION
Because adaphostin demonstrates activity against a wide
range of hematological malignancies in vitro, there is consider-
able interest in understanding its mechanism of action. This
study has demonstrated that adaphostin generates ROS within
intact cells and causes oxidative DNA damage. Additional
experiments designed to identify the source of these ROS indi-
cated that adaphostin is oxidized to the corresponding quinone
in aqueous buffers. In the reducing environment of the intact
cell, however, the quinone is not detectable. Instead, adaphos-
tin is concentrated by up to 3000-fold inmitochondria, where it
inhibits respiratory complex III. Consistent with previous
reports that inhibition of mitochondrial electron transport can
6 Higher CysNAc concentrations could not be utilized because they dimin-
ished HCT116 cell colony formation by themselves.
FIGURE 7. Docking of adaphostin into the Qi site of cytochrome b in silico. A, close-up view of adaphostin bound in the Qi site of the cytochrome b subunit
of the cytochrome bc1 complex; B and C, overlays of the adaphostin complex (green) with the antimycin A complex (yellow).
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result in generation of ROS (48–50), our study has also demon-
strated increased ROS levels upon incubation of adaphostin
with mitochondria under cell-free conditions. These results
have potentially important implications for the current under-
standing of the cytotoxic action of adaphostin.
The results of previous studies demonstrated that treatment
of cells with adaphostin results in enhanced CM-DCF fluores-
cence (4, 6), providing presumptive evidence of ROS genera-
tion. Additional experiments indicated that the cytotoxicity of
adaphostin is enhanced by glutathione depletion and dimin-
ished by treatment with CysNAc (4, 6). The results of the pres-
ent analysis confirmed and extended these previous findings by
providing direct evidence of oxida-
tive DNA damage after adaphostin
treatment (Fig. 1C). These results
rule out the possibility that the
enhanced CM-DCF fluorescence
merely represents an effect of ada-
phostin on ATP-binding cassette
proteins (7, 8).
While this work was in progress,
Hose et al. (51) reported that ada-
phostin treatment results in an
increase in cytosolic free iron as
assessed by decreased fluorescence of
the iron-sensitive dye PhenGreen SK
and that the iron chelator desferri-
oxamine diminishes adaphostin-in-
duced cytotoxicity, prompting the
authors to conclude that mitochon-
drial release of iron contributes to
the ROS elevation and cytotoxicity
of adaphostin. Our subsequent
experiments showed, however, that
the diminished dye fluorescence
might be a result of adaphostin-
mediated quenching (26), that
increased cytosolic iron could not
be detected by mass spectroscopy,7
and that desferrioxamine failed to
protect K562 cells from adaphostin-
induced cytoxicity.7,8 These obser-
vations, whichmight differ from the
results of Hose et al. because of
cell type-specific differences in the
effects of adaphostin on iron
sequestration, prompted us to
search further for the source of ada-
phostin-induced ROS.
Several lines of evidence indicate
that this increase in ROS levels is
independent of any inhibitory effect
of adaphostin on Bcr/Abl. First,
increased ROS levels are evident in
K562 cells within 15–30min (Fig. 1)
(4), whereas inhibition of Bcr/Abl-
mediated phosphorylation is not
evident for 4–6 h (2). Second, inhi-
bition of Bcr/Abl and Abl by imatinib mesylate is accompanied
by decreased ROS levels (52), whereas adaphostin causes an
increase in ROS levels. Finally, adaphostin-induced increases in
ROS levels are observed in a variety of Bcr/Abl-negative cells,
including the Jurkat, ML-1, MOLT-4, A549, and HCT116 cell
lines, as well as in chronic lymphocytic leukemia and acute
myelogenous leukemia clinical samples (Figs. 8C and 9) (4–6).
On the basis of the dihydroquinone structure of adaphostin,
we anticipated that this compoundmight undergo oxidation to
7 S. B. Lee and S. H. Kaufmann, unpublished data.
8 J. Chandra, personal communication.
FIGURE 8. Adaphostin-induced ROS generation in the presence of mitochondria. A, adaphostin was added
to isolated rat mitochondria in MIB containing 5 mM succinate, 1 M rotenone, and 24 mM CysNAc (NAC) or 100
M butylated hydroxyanisole (BHA). The CCCP-stimulated oxygen consumption rate was measured using an
oxygen electrode as illustrated in Fig. 4. Extensive preliminary experiments indicated that CysNAc and buty-
lated hydroxyanisole by themselves had no effect on rat mitochondrial oxygen consumption (data not shown).
B, aliquots of MIB without or with isolated rat liver mitochondria (1 mg/ml protein) were incubated for 1 h at
37 °C in the absence or presence of 100 M adaphostin and/or 600 units/ml catalase. At the completion of the
incubation, Amplex Red was added to assay the H2O2 generated. C, MOLT-4 cells (upper panel) or MOLT-4 rho
0
cells (lower panel) treated with 10 M adaphostin (Ada) or diluent (dimethyl sulfoxide (DMSO)) for 30 min were
stained with CM-H2DCF diacetate and subjected to flow cytometry. D, shown is a summary of CM-H2DCF
diacetate staining experiments examining rho0 cells. Inset, the cellular concentration of adaphostin in MOLT-4
rho0 cells, determined as described in the legend to Fig. 3 (B and E), was compared with that in MOLT-4 cells in
the same experiments. Error bars represent the means 	 S.D. of three (A, B, and inset in D) and four (D) inde-
pendent experiments.
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the corresponding quinone in aqueous buffer at ambient oxy-
gen tension. Consistent with this hypothesis, the quinone
derivative of adaphostinwas readily detected, alongwith super-
oxide radical and H2O2, when adaphostin was incubated in
aqueous buffers (Fig. 2,A–D). Under conditions encountered in
cells, however, this oxidation was not detectable (Fig. 3A).
Instead, adaphostin was concentrated 3000-fold in mitochon-
dria (Fig. 3, B–D), where it inhibited mitochondrial respiration
(Fig. 4) and contributed to generation of ROS (Fig. 8B).
It is important to emphasize that these effects of adaphostin
onmitochondria are upstream rather than downstream of ROS
generation. In particular, treatment of isolated mitochondria
with adaphostin in the presence of ROS scavengers also inhib-
ited mitochondrial respiration (Fig. 8A). These results suggest
that adaphostin blocks mitochondrial respiration directly
rather than by generating ROS, which in turn damage mito-
chondria and block electron transport. Moreover, adaphostin-
induced increases in ROS levels were markedly diminished in
cells lacking oxidative phosphorylation (Fig. 8, C and D), pro-
viding further support for the view that mitochondrial electron
transport contributes to adaphostin-induced ROS.
Additional experiments demonstrated that adaphostin
attenuated respiration of isolatedmitochondria incubated with
the complex I substrates pyruvate and malate (Fig. 4, C and D)
or the complex II substrate succinate (Fig. 4C). Coupled with
the failure of adaphostin to inhibit pyruvate and succinate
dehydrogenases (Fig. 5), these results suggested that adaphos-
tin might act downstream of complexes I and II. Consistent
with this hypothesis, adaphostin was found to inhibit the ability
of reduced decylubiquinone to reduce cytochrome c (Fig. 6).
These results indicate that, like antimycinA and certain ubiqui-
none analogs (53–55), adaphostin is
an inhibitor of respiratory complex
III. Consistent with this possibility,
an in silico docking study performed
without any prior assumption about
the mode of adaphostin binding to
the Qo and Qi sites of cytochrome b
demonstrated that the Qi site could
accommodate adaphostin in a bind-
ing mode similar to that of antimy-
cin A (Fig. 7). Additional analysis
demonstrated that, like antimycinA
(48, 49), adaphostin enhancedmito-
chondrial generation of ROS (Fig.
8B), providing an explanation for
the increased ROS in adaphostin-
treated cells.
Despite the fact that adaphostin
and antimycin A both inhibit com-
plex III, there are important differ-
ences between these agents. A
previous study suggested that anti-
mycin A is a general cellular poison
that exhibits little selectivity for
neoplastic compared with normal
cells (56). In contrast, previous stud-
ies have demonstrated that ada-
phostin is selective for chronicmyelogenous leukemia (1, 2) and
chronic lymphocytic leukemia (4, 5) compared with normal
bone marrow progenitors and normal lymphocytes. Although
the basis for this selectivity is currently unknown, previous
studies have demonstrated enhanced uptake of a number of
aromatic cationic dyes into themitochondria of neoplastic cells
(57–60). Additional experiments examining the mechanism of
uptake of adaphostin into mitochondria are required to deter-
mine whether the propensity of mitochondria in neoplastic
cells to concentrate aromatic cationic compounds contributes
to the observed selectivity of adaphostin for leukemic as
opposed to normal leukocytes.
Even though this study demonstrated a remarkable concen-
tration of adaphostin within mitochondria, it is important to
note that almost 40% of the total cellular drug was also found in
nuclei. We cannot at present rule out the possibility that
nuclear accumulation of adaphostin also contributes to the
cytotoxicity of this agent. Nonetheless, previous results from
three laboratories demonstrating the ability of reducing agents
such as CysNAc to inhibit the cytotoxicity of adaphostin (4–6)
support the view that mitochondrial generation of ROS in the
presence of adaphostin (Fig. 8B) plays a predominant role in the
cytotoxicity.
These observations distinguish the action of adaphostin
from those of a large class of anticancer drugs that are quinones.
Previous studies have suggested that the cytotoxicity of these
quinones is due to redox cycling between the quinone and
semiquinone free radical, which generates ROS in the process
(9). In contrast, our results provide little evidence for sponta-
neous oxidation of adaphostin in intact cells, but instead indi-
cate that mitochondria play a role in the generation of ROS by
FIGURE 9. Adaphostin-induced ROS generation and killing in solid tumor cell lines. A and B: left panels,
HCT116 and A549 cells, respectively, treated with 10 M adaphostin (Ada) or diluent for 30 min were stained
with CM-H2DCF diacetate and subjected to flow cytometry. Right panels, the bar graphs indicate the means 	
S.D. of three independent determinations. C and D, HCT116 and A549 cells, respectively, treated for 4 h with 6
mM (C) or 24 mM (D) CysNAc (NAC) or with 0.5 mM BSO were treated with the indicated concentrations of
adaphostin for 24 h, washed, and allowed to form colonies. Error bars represent the means 	 S.D. of triplicate
determinations.
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this antitumor hydroquinone. Whether complex III is a target
of other hydroquinones and possibly even quinones remains to
be determined.
Finally, because the involvement of complex III in adaphos-
tin-induced increases inROS levels suggested that the cytotoxic
effects of this agent should not be limited to leukemia cells, we
examined the effects of this agent in solid tumor cell lines.
Drug-induced ROS elevations and sulfhydryl-sensitive killing
were observed in HCT116 colon cancer cells, A549 lung cancer
cells, and OVCAR5 ovarian cancer cells (Fig. 9) (data not
shown). While this manuscript was under review, Long et al.
(61) also reported that adaphostin induces ROS-mediated cyto-
toxicity in glioblastoma cells. Collectively, these observations
suggest that adaphostinmight be active against awide variety of
cancer cell types.
In summary, adaphostin is concentrated in mitochondria,
where its ability to inhibit respiratory complex III appears to
contribute to the intracellular generation of ROS. Moreover,
this study has demonstrated adaphostin-induced oxidative
damage of DNA in intact cells. Based on the uniquemechanism
of action of this agent and its demonstrated selectivity for leu-
kemia cells in vitro, further study of this agent appears to be
warranted.
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